Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions

Area of Science:

• Oncology
• Immunotherapy
• Vaccinology

Background:

• Therapeutic cancer vaccines represent a key immunotherapy strategy for genitourinary (GU) cancers, aiming to elicit antitumor immune responses via T-cell activation.
• While some vaccines like bacillus Calmette-Guérin and sipuleucel-T have demonstrated success, monotherapy often yields limited clinical benefits due to factors like tumor heterogeneity and immunosuppressive microenvironments.
• Existing vaccine platforms are safe and immunogenic in prostate, renal cell, and urothelial cancers, but their efficacy is generally modest.

Purpose of the Study:

• To review the current landscape of therapeutic cancer vaccines in genitourinary malignancies.
• To identify challenges and limitations hindering vaccine efficacy.
• To highlight emerging strategies and future directions for improving vaccine-based immunotherapy in GU cancers.

Main Methods:

• Literature review of preclinical and clinical studies on therapeutic cancer vaccines in GU cancers.
• Analysis of factors affecting vaccine efficacy, including tumor biology and the tumor microenvironment.
• Examination of current and future therapeutic strategies, including combination therapies and personalized vaccine design.

Main Results:

• Multiple vaccine platforms have shown safety and immunogenicity across various GU cancers.
• Limited clinical efficacy of monotherapy is attributed to tumor heterogeneity, poor immune infiltration, and immunosuppressive tumor microenvironments.
• Ongoing research focuses on multi-antigen targeting, enhanced antigen presentation, and combination therapies to improve antitumor activity.

Conclusions:

• Therapeutic cancer vaccines hold significant potential for GU cancers, but overcoming current limitations is crucial.
• Combination strategies involving immune checkpoint inhibitors, radiotherapy, and targeted agents are promising avenues.
• Advances in personalized vaccine design and delivery systems, alongside addressing manufacturing and biomarker challenges, are essential for future success in GU malignancies.